Siddiqui, Faraz orcid.org/0000-0002-2253-3911, Huque, Rumana and Dogar, Omara Fatima orcid.org/0000-0002- 7122-8403 (2017) Despite a general decline in smoking rates in the UK, smoking prevalence remains high among young adults, pregnant women and those from socioeconomically disadvantaged backgrounds. These three groups are also more likely to benefit from targeted smoking cessation interventions. Clinical contact between health professionals and patients who smoke creates an opportunity for offering cessation interventions and to reduce smoking-related harm. This article summarises evidence, based on high-quality systematic reviews, on smoking cessation interventions that could be offered by health professionals coming in to contact with patients who smoke. The evidence presented here suggests that brief advice by a health professional is beneficial in achieving smoking cessation and so is intensive behavioural support alone or in combination with pharmacotherapies (nicotine replacement therapies (NRTs), bupropion and varenicline). Pharmacotherapies are also effective individually in promoting smoking cessation; a combination of NRTs (oral or skin patch) can be particularly helpful in promoting cessation among highly dependent smokers. Pharmacotherapies in combination with behavioural support delivered in health care settings are more effective than when used alone and delivered in community settings, respectively.
C urrently, the proportion of adult smokers in the UK has halved (19%) down from a peak of 46% in 1970s. he proportion of men aged 16 and above who smoked cigarettes was 20% whereas 17% of women smoked in 2014 (Oice for National Statistics (ONS), 2014). More than twice as many people in socioeconomically disadvantaged areas smoke compared to those in aluent areas (33.8% vs 14.1%) (Simpson et al, 2010) . he phenomenon remains consistent in adolescents; the odds of smoking among adolescents living in the UK are also seen to increase with increasing area-level deprivation (Levin KA et al, 2014) . In men, more than half of the risk of premature mortality between social classes is secondary to tobacco smoking (Jarvis and Wardle, 1999) . Furthermore, two thirds of deaths among women who smoke are due to smoking itself; resulting in a loss of at least 10 years of average lifespan (Pirie et al, 2013) . However, 90% of deaths due to smoking can be avoided if a person quits before the age of 40 years; if before the age of 30, 97% of excess deaths can be avoided (Pirie et al, 2013) .
Smoking cessation
Given that smoking is the single most preventable cause of premature mortality (Jha et al, 2006) , the UK government has introduced a range of initiatives, such as the UK stop smoking services, in recent decades to reduce smoking related deaths (Bauld et al, 2016) . Between 2001 and 2007, access to specialist advice on smoking cessation increased from 43.6% to 84.0% (Simpson et al, 2010) and data from stop smoking services in England show that 35% of service users achieve abstinence four weeks ater quitting (West et al, 2013) . he long-term quit rate (52 weeks ater quitting) of smokers who try to quit on their own is approximately 3% (Hughes et al, 2004) which is lower than the quit rate seen in the English stop smoking services (8%) and particularly lower than those of the specialist one-to-one and group services (10% (95% CI 8-11%) and 12% (95% CI 11-14%), respectively) (Bauld et al, 2016) . However, comparatively higher rates of smoking are still found among younger adults (Levin KA et al, 2014) , pregnant women (Meernik and Goldstein, 2015) and those who are the most socioeconomically disadvantaged (Hiscock et al, 2012) , including ethnic minorities (Liu et al, 2012) . If targeted appropriately, these groups are most likely to beneit from Stop Smoking Services. he highest quit rates in the UK were found among those from socioeconomically deprived areas (7.2%) and young adults (16-25 years: 7.1%) (Simpson et al, 2010) . Around 45% of women tend to stop smoking either just before or during their pregnancy (Woodby et al, 1999) ; however, only a third are able to maintain continuous abstinence ater a year (Centers for Disease Control and Prevention (CDC), 2002). Smoking cessation by health care providers he majority of smokers who wish to quit ind it very diicult to give up on their own without proper professional support, leading them to several futile quit attempts (Fiore, 2000) . hose attending Stop Smoking Services are four times more likely to give up their smoking habit successfully than those attempting to quit on their own (National Institute for Health and Care Excellence (NICE), 2008). Generally, 79-90% of smokers are willing to quit (National Institute of Health (NIH) State-of-the-Science Panel, 2006) and 70% of them visit a health professional to seek relevant support (Cherry et al, 2003) . Nurses, the largest group of health professionals involved in the majority of clinical contacts, have an opportunity to inluence the smoking behaviour of their patients and reduce smoking-related harm (Percival et al, 2003; Whyte and Kearney, 2003) . A recent systematic review found a signiicantly profound efect of nurse-delivered interventions on increasing the likelihood of quitting among patients who smoked (RR 1.29, 95% CI 1.20-1.39) compared to control or usual care (Rice et al, 2013) .
Clinical Focus
he NICE guidelines for health professionals recommend using a range of smoking cessation 'interventions' and activities, including pharmacological (nicotine replacement therapy (NRT), bupropion and varenicline) as well as non-pharmacological (behavioural therapies) options (NICE, 2008) .
his article ofers a practical, accessible and evidence-based guide on smoking cessation therapies for nurses providing health care in a variety of settings. It summarises evidence from a relevant Cochrane reviews on smoking cessation interventions, in line with the NICE recommendations (2008) and contemporary views on behavioural change theories and techniques (BCTs). 
Defining quit
Smoking cessation experts have deined speciic criteria as follows, referred to as the Russell standard, to conirm when a smoker is considered to have quitted (West, 2005) :
A 'self-reported 4-week quitter' is a treated smoker assessed (face-to-face, by postal questionnaire or by telephone) 4 weeks ater the assigned quit date who declares that s/he has not smoked even a single puf of a cigarette in the past 2 weeks A 'carbon-monoxide (CO) veriied 4-week quitter' is a self-reported 4-week quitter and his/her expired-air CO is assessed 4 weeks ater the assigned quit date and found to be less than 10 ppm A '52-week quitter' is a treated smoker assessed (face-to-face, by postal questionnaire or by telephone) 52 weeks ater the designated quit date and declares that s/he has not smoked more than ive cigarettes in the past 50 weeks.
Smoking cessation therapies in health care practice

Brief interventions
Brief interventions by a health professional include opportunistic advice, discussion, negotiation or encouragement and, where necessary, referral to a specialist service, typically lasting less than 10 minutes (NICE, 2008) .
Compared to no advice, brief advice by practitioners (physician or physician supported by other health care workers) to smokers increases the likelihood of successful quit attempts at 6 months (RR 1.66, 95% CI: 1.42-1.94). Assuming an unaided smoking cessation rate of 2-3%, brief advice can increase the cessation rate by a further 1-3% .
Behavioural support interventions/counselling (individual or group)
Behavioural support interventions are delivered through face-to-face consultations ('individual behavioural therapy') or consultations in groups ('group behavioural therapy') consisting of weekly appointments for the irst 4 weeks of a quit attempt, where the smokers receive information, advice and encouragement and some form of behavioural change intervention (NICE, 2008) . 'Group behavioural therapy' , in addition to applying behavioural change techniques, ofers an opportunity for social learning and mutual support . Telephone counselling and quitlines are also used to support those who are considering quitting, and those who have recently quitted (NICE, 2008) .
Individual behavioural therapy
Individual behavioural therapy oten takes the form of advice, discussion, encouragement and activities to help people stop smoking successfully. hese activities are designed to change targeted behavioural patterns, involving three essential conditions: capability, opportunity and motivation-core to the framework of the 'behavioural system' (Michie et al, 2011a) . he 'active ingredients' of behavioural support interventions are classiied into four functions: ■ Directly addressing motivation, e.g. by providing rewards dependent on abstinence ■ Maximising self-regulatory capacity, e.g. facilitating barrier identiication and problem solving ■ Promoting adjuvant activities, e.g. advising on stopsmoking medication ■ Supporting other BCTs, e.g. building general rapport (Michie et al, 2011b) . In total, 43 such behavioural change techniques have been identiied for this purpose (Michie et al, 2011b) and should form the core of behavioural support interventions for smoking cessation.
Behavioural support interventions delivered via face-to-face sessions by a trained health care worker achieved higher success rates in quitting at 6 months (RR 1.39, 95% CI: 1.24-1.57) compared to brief interventions delivered by health workers other than nurses and doctors. he behavioural support interventions, typically involving intensive counselling for more than 10 minutes, included a review of the smoking history and the motivation to quit, identiication of high-risk situations, and proposing problem-solving strategies to cope with such situations . However, when individual behavioural support interventions were compared to brief interventions, irrespective of who is delivering these, there was insuicient evidence to support any marginal beneit (ive trials, RR 0.96, 95% CI: 0.74-1.25) .
Group behavioural therapy
Group therapies consist of information, advice and encouragement over several sessions. Such therapies are likely to double the chances of cessation among smokers compared to self-help materials alone (RR 1.98, 95% CI:
Clinical Focus © 2017 MA Healthcare Ltd 1.60-2.46) . However, there is limited evidence on whether adding group therapies to brief interventions received from health professionals produced any extra beneit .
here is also not enough evidence to suggest whether group behavioural therapies are more (or less) efective or cost-efective than individual behavioural therapies .
Nicotine replacement therapy
Mode of action Of all tobacco ingredients, nicotine is the most addictive, but perhaps least harmful substance. herefore, nicotine replacement therapy (NRT) is a highly attractive cessation tool, as it reduces motivation to smoke by countering the physiological and psychomotor efects of nicotine withdrawal, easing the transition to sustained abstinence (West and Shifman, 2001 ). Commercially-formulated NRTs are absorbed either through the skin, in the form of transdermal patches, or through oral mucosa, in the form of chewing gum, nasal spray, inhalers and lozenges/tablets, all of which deliver nicotine more quickly than patches, but less quickly than cigarettes.
All commercially available forms of NRT increase the likelihood of smoking cessation by about 50-70% (RR 1.60, 95% CI: 1.53-1.68) compared to placebo or non-NRT controls (Stead et al, 2012) . he relative risks of smoking cessation for various forms of NRT are: nicotine gum 1.49 (95% CI: 1.40-1.60), nicotine skin patch 1.64 (95% CI: 1.52-1.78), nicotine inhaler 1.90 (95% CI: 1.36-2.67), tablets and lozenges 1.95 (95% CI: 1.61-2.36) and nicotine nasal spray 2.02 (95% CI: 1.49-2.73) independent of the duration of use, intensity of any additional behavioural support or the delivery settings (Stead et al, 2012) .
Combinations of nicotine skin patches and oral NRTs can signiicantly increase the chances of successful cessation attempts among heavy smokers (RR 1.34, 95% CI: 1.18-1.51) compared to using a single type alone (Stead et al, 2012) .
Initiating NRT use shortly before setting the quit date does not signiicantly increase the chances of successful cessation among smokers (RR 1.18, 95% CI: 0.98-1.51), compared to starting NRT on the quit date (Stead et al, 2012) . Moreover, the evidence is limited on the usefulness of NRTs in increasing the chances of successful quitting among those who smoke less than 10-15 cigarettes in a day.
Dosing
Skin patches of NRT are available in several diferent doses, and can deliver up to 44 mg of nicotine over a 16-or 24-hour period, with optimal results achieved for 25 mg patches (Stead et al, 2012) . Application of NRT skin patches for extended durations does not suggest a diference in cessation rates; however, both 16 vs 24 hour application methods are efective for smoking cessation when compared to a placebo. Nicotine lozenges and nicotine chewing gum are available in both 2 mg and 4 mg strengths. here is limited evidence on any remarkable diference between the various forms of NRT or its use beyond 8 weeks of therapy (Stead et al, 2012) . Heavier smokers, highly dependent on nicotine, might beneit from a higher dose of nicotine gum (4 mg compared to 2 mg), but the evidence is weak in proposing the beneits of using higher doses of nicotine patch (Stead et al, 2012) .
Side efects he use of NRT is considered relatively safe with minor adverse efects reported. hese include skin sensitivity and irritation in patch users, afecting around 54% of users (Fiore et al, 1992) , buccal mucosal irritation, hiccoughs, jaw pain and orodental problems from gum and tablets, and local irritation at the site of administration from nicotine inhalers and nasal sprays (Stead et al, 2012) . here is lack of evidence to support that NRT increases the risk of cardiovascular events, cancers, stroke or reproductive/ developmental efects (Lee and Fariss, 2016) ; however, a signiicant association with heart palpitations and chest pain (RR 1.88 95% CI 1.37-2.57) has been observed with its use (Stead et al, 2012) .
Other pharmacotherapies
Varenicline and bupropion are two popular forms of pharmacotherapies used to aid smoking cessation in practice. In addition, newer drugs like nortriptyline and cytisine have also been used recently.
Mode of action
When smokers quit, they experience cravings to smoke and unpleasant mood changes due to the nicotine withdrawal. Varenicline is a nicotine receptor partial agonist that aims to reduce such symptoms. It counteracts the efects of nicotine on the neuronal acetylcholine receptors (nAChRs), based on the naturally occurring alkaloid compound cytisine (Papke and Heinemann, 1994; Slater et al, 2003) . Nicotine withdrawal might precipitate depression, as nicotine appears to have anti-depressive properties. Bupropion (an anti-depressant) can substitute for this efect by inluencing the neurotransmitters and receptors involved in nicotine addiction (Benowitz and Peng, 2000; Kotlyar et al, 2001 ).
Nortriptyline (a tricyclic antidepressant) is believed to increase noradrenergic activity; it may be prescribed when irst-line treatments have been unsuccessful (Hughes et al, 2014) .
Bupropion and nortriptyline both signiicantly increase the likelihood of smoking cessation (buproprion-RR 1.62, 95% CI: 1.49-1.76; nortriptyline-RR 2.03, 95 %CI: 1.48-2.78) compared to placebo (Hughes et al, 2014) . Both are considered to be equally efective and of similar eicacy as NRT in achieving long-term cessation; however, their addition to NRT does not provide any additional beneit (Hughes et al, 2014) .
Dosing
Varenicline increases the chances of successful smoking cessation by more than two-to threefold (OR 2.88, 95% CI: 2.40-3.47) at 6 months relative to placebo (Cahill et al, 2013) . A reduced dosage is efective compared to a standard dosage (RR 1.25, 95% CI: 1.00-1.55) relative to placebo for long-term smoking cessation. A lower dose has fewer and less severe side efects and achieves cessation rates roughly similar to NRT or bupropion (Cahill et al, 2016) . When compared to bupropion, varenicline signiicantly increases the chances of successful smoking cessation (OR 1.59, 95% CI: 1.29-1.96) (Cahill et al, 2016) . It is also more efective than a single form of NRT (OR 1.57, 95% CI 1.29-1.91), but not more efective than combination NRT (OR 1.06, 95% CI 0.75-1.48) (Cahill et al, 2013) . here is also limited evidence that varenicline might have a beneicial role in relapse prevention compared to placebo (RR 1.24, 95% CI 1.08-1.42) at 52 weeks (Cahill et al, 2016) .
he standard dosage of varenicline used in clinical trials is 1.0 mg twice a day (Cahill et al, 2016) . he standard dosage of bupropion in practice is 150 mg once a day for 3-6 days, increased to 150 mg twice a day to be continued for 7-12 weeks, initiated a week before the quit date of the smoker (Hughes et al, 2014) .
Side efects
he adverse events with bupropion use include insomnia, dry mouth, nausea, and, rarely, seizures (1 in 1000) (Hughes et al, 2014) . he adverse events reported with varenicline use mainly include mild-to-moderate levels of nausea. However, there is inconclusive evidence suggesting links with serious adverse events including depressed mood, agitation, suicidal thinking and cardiovascular problems (Cahill et al, 2016) . Although, a study from homas et al (2013) found that neither varenicline nor bupropion increased the risk of fatal or non-fatal selfharm, or increased the risk of depression treated with antidepressants compared with NRT alone. he use of cytisine is shown to have a beneicial efect in achieving smoking cessation compared to placebo (RR 3.98, ). Cytisine also demonstrated beneit when compared to NRT (RR 1.43, 95% CI 1.13-1.80) with abstinence rates of 21.8% vs 15.3% at 6 months (Cahill et al, 2016) . Adverse events with cytisine use include Gastrointestinal disorders, sleep disorders, nausea and vomiting; the rates for these adverse events are signiicantly higher than placebo (West et al, 2011) and NRT (Walker et al, 2014) .
here is insuicient evidence to support the use of other antidepressive agents (Monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, Electronic cigarettes heat a liquid into an aerosol for inhalation. St. John's wort, venlafaxine, and dietary supplement S-adenosyl-L-methionine (SAMe) for smoking cessation (Hughes et al, 2014 .
Electronic cigarettes
Electronic cigarettes or electronic nicotine delivery systems (ENDs) are devices that heat a liquid into an aerosol for inhalation. he liquid usually comprises propylene glycol and glycerol, with or without nicotine and lavours . here is wide variation between diferent types of electronic cigarettes; the more recent generations of electronic cigarettes have a very similar nicotine delivery proile to combustible cigarettes. here has been a steady growth in sales of electronic cigarettes since they appeared on the market in 2006 . Electronic cigarettes are considered a less harmful alternative to combustible cigarettes and promoted as a tool for harm reduction in the UK (McNeill et al, 2015; Britton et al, 2016) . However, the role and impact of electronic cigarettes remain a major public health debate (McNeill et al, 2015) as there is limited evidence on the long-term health efect on active and passive use of e-cigarettes (Latif and Nair, 2016) .
A recent Cochrane review showed that using electronic cigarettes containing nicotine increased the chances of stopping smoking in the long-term compared to using an electronic cigarettes without nicotine . Combined results from the two randomised controlled trials also suggest that use of a nicotine-containing electronic cigarettes was associated with higher abstinence rates than placebo electronic cigarettes use (RR 2.29, 95%CI 1.05-4.96) . However, authors could not determine if electronic cigarettes was better than a nicotine patch in helping people stop smoking, because the number of participants in the study was low. None of the studies found that smokers who used electronic cigarettes short-to mid-term (for 2 years or less) had an increased health risk compared to smokers who did not use electronic cigarettes. he authors acknowledged that the quality of the evidence overall was low due to the small number of studies, although these studies were well conducted .
Effective combinations
Behavioural support and pharmacotherapies individually aid smokers in successful attempts to stop smoking. Many guidelines recommend combining the two interventions to assist people in stopping smoking, but there are some combinations that are more efective than others, and some that work better in certain settings than in others.
A combination of behavioural support and pharmacotherapy can increase the chances of successful smoking cessation by 70-100% (RR 1.83, 95% CI 1.68-1.98) compared to controls receiving brief advice, usual care or less intensive behavioural support (Stead and Lancaster, 2016) . Combination therapies demonstrate a greater beneit when delivered in health-care settings (RR 1.97, 95% CI 1.79-2.18) than when used in community-based settings (RR 1.53, 95% CI 1.33-1.76) (Stead et al, 2016) .
Using intensive behavioural support (face-to-face or via telephone) as an adjunct to pharmacotherapy increases the chances of successful smoking cessation by about 10-40% (face-to-face RR 1.12, 95% CI 1.04-1.20; telephone RR 1.28, 95% CI 1.17-1.41) relative to controls using pharmacotherapy alone (Stead et al, 2015) . Moreover, increasing the intensity of behavioural support in people attempting to stop smoking with pharmacotherapy increases the chances of successful smoking cessation by another 10-25% (RR 1.17, 95% CI 1.11-1.24) relative to less-intensive behavioural support. However, there is insuicient evidence to support any beneicial efect of behavioural support when added to nortriptylin or varenicline (Stead et al, 2015) .
Smoking in pregnancy
he addition of NRT to behavioural support may be an efective strategy to promote smoking cessation in pregnant women (RR 1.41, 95% CI 1.03-1.93); however, the interpretation should be made with caution, as the efect is lower in placebo randomised controlled trials
Key Points
■ Brief advice by a health professional is beneficial in achieving smoking cessation ■ Intensive behavioural support alone and in combination with pharmacotherapies is effective in promoting smoking cessation ■ Pharmacotherapies (nicotine replacement therapy (NRT), bupropion, nortriptyline, varenicline and cytisine) are individually effective in promoting smoking cessation ■ A combination of NRTs (slow and rapid release) are effective for promoting cessation among harder smokers ■ Combination therapies of behavioural support and pharmacotherapy are more effective than pharmacotherapies alone in promoting cessation among smokers when delivered in health care settings ■ There is limited evidence of benefit from electronic cigarettes in smoking cessation (Coleman et al, 2015) .
'Smoking reduction' vs 'abrupt cessation'
A reduction in smoking before the quit date and stopping abruptly, with no prior reduction, produces comparable smoking cessation rates (Lindson-Hawley et al, 2012) . Trials using the nicotine-assisted reduction to stop (NARS) strategy indicate that it is efective (RR 2.06, 95% CI: 1.34-3.15) in achieving sustained abstinence in smokers who are otherwise unable to attempt an abrupt quit (Moore et al, 2009 ). In addition, smokers who do not wish to quit might be helped to cut-down the number of cigarettes they smoke and ultimately to quit smoking in the long term despite original intentions not to do so (LindsonHawley et al, 2016) . NRT is found to be efective in reducing the number of daily cigarettes smoked by 50% (RR 1.75 95%CI 1.44-2.13) in such users, although this was not relected in the carbon monoxide and cotinine levels of the users. NRT was also found to be efective for long-term smoking quit in these users (RR 1.87, 95%CI 1.43-2.44); however, the quality of evidence was assessed to be low. here is insuicient evidence at this time for the application of other methods (pharmacological intervention, electronic cigarettes, snus, nicotine patches and low tar cigarettes) in demonstrating a smoking reduction or complete cessation in smokers unwilling or unable to quit (Lindson-Hawley et al, 2016) .
Adjunct aids
here is insuicient evidence to suggest a possible beneicial role of smoking cessation and weight gain therapies in limiting post-cessation weight gain in people stopping smoking in the long term (Farley et al, 2012) and also of exercise interventions aiming to increase cessation rates among smokers (Ussher et al, 2014) . he role of social support by peer or partner in improving smoking cessation rates among pregnant women or people attempting to quit remains inconclusive due to limited evidence (Park et al, 2012) . Similarly, although there is evidence of a potential beneit from peer support provided to pregnant women for smoking cessation (RR 1.09, 95%CI 1.01-2.19), the evidence at this time is limited (Chamberlain et al, 2013) .
Conclusions
he research on smoking cessation suggests that diferent therapies and their combinations work better in certain settings than in others, and need to be tailored according to the patient type and their preferences. Overall, even brief advice by a trained health professional is beneicial in achieving smoking cessation in a patient presenting to health services, but to a lesser extent than behavioural support alone or in combination with pharmacotherapies (NRTs, bupropion and varenicline). Individual pharmacotherapies are efective for smoking cessation, however, they are to be more efective in combination with behavioural support. Combination NRTs (oral or skin patch) are observed to be particularly helpful in promoting cessation among heavy smokers compared to light smokers. 
CPD relective questions
■ What would you prescribe to a young (25 year old) male smoker who visits you for cessation advice? He is generally in good health and smokes more than 20 cigarettes a day. ■ Would you prescribe NRT a week before the smoker sets the quit date or from their quit date? ■ What would be the best course of therapy for a pregnant women seeking advice on quitting smoking as she is 3 months pregnant? ■ If a patient is seeing you for some medical condition and not necessarily for smoking cessation but s/he smokes 5-10 cigarettes a day. Would you consider giving them 'brief advice' or 'no advice' because you might be pressed for time given your busy clinic?
